专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008017507A3 NANOPARTICLE NUCLEIC ACID BONDING COMPOUND CONJUGATES FORMING I-MOTIFS 审中-公开
标题翻译：纳米粒子核酸连接化合物形成I-MOTIFS
公开(公告)号：WO2008017507A3
公开(公告)日：2009-03-19
申请号：PCT/EP2007007109
申请日：2007-08-10
申请人： ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE , LEONARD PETER , BUDOW SIMONE , SEELA FRANK
发明人： LEONARD PETER , BUDOW SIMONE , SEELA FRANK
IPC分类号： A61K47/48 , C09K19/04 , C09K19/38 , G01N33/58
CPC分类号： C09K19/52 , A61K47/6923 , B82Y5/00 , Y10T436/143333
摘要： The present invention concerns the field of nanoparticle bioconjugates which form an i-motif or an i-motif related structure (compositions) (i) without or (ii) with at least one further nucleic acid binding compound (Figure 1). The i-motif base pairs can be charged or non-charged as shown in Figure (1). Their assembly can be controlled by the pH value or temperature. At least one of these nucleic acid binding compounds has to be attached at least to a nanoparticle. The methods provide compositions used for DNA driven programmable nanoparticle assemblies, electronic circuits, diagnostic detection tools, biosensors, memory storage devices, diagnostic devices for biomolecule sequencing and detection, drug delivery, application in tumour diagnostics and treatment, nanomachines, nanofabrication, nanocatalysis, nanoarrays and nanoscaled enzyme reactors.
摘要翻译：本发明涉及形成i-基序或i-基序相关结构（组合物）的纳米颗粒生物缀合物的领域（i）不具有或（ii）至少一种其它核酸结合化合物（图1）。 i图案碱基对可以带电或不带电，如图（1）所示。它们的组装可以通过pH值或温度来控制。这些核酸结合化合物中的至少一种必须至少连接到纳米颗粒上。该方法提供用于DNA驱动的可编程纳米颗粒组件，电子电路，诊断检测工具，生物传感器，记忆存储装置，用于生物分子测序和检测的诊断装置，药物递送，肿瘤诊断和治疗中的应用，纳米机械，纳米制造，纳米催化，纳米阵列和纳米级酶反应器。

2. 发明申请

WO0068422A3 HIGH DENSITY LABELING OF DNA WITH MODIFIED OR "CHROMOPHORE" CARRYING NUCLEOTIDES AND DNA POLYMERASES USED 审中-公开
标题翻译：具有改性或“色素”的DNA的高密度标记携带核酸和使用的DNA聚合物
公开(公告)号：WO0068422A3
公开(公告)日：2002-04-04
申请号：PCT/EP0004036
申请日：2000-05-05
申请人： ROCHE DIAGNOSTICS GMBH , MUEHLEGGER KLAUS , ANGERER BERNHARD , SEELA FRANK , ANKENBAUER WALTRAUD , AUGUSTIN MARTIN , GUMBIOWSKI KARIN , ZULAUF MATTHIAS
发明人： MUEHLEGGER KLAUS , ANGERER BERNHARD , SEELA FRANK , ANKENBAUER WALTRAUD , AUGUSTIN MARTIN , GUMBIOWSKI KARIN , ZULAUF MATTHIAS
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6816 , C12Q2563/131 , C12Q2525/101
摘要： Subjects of the inventions are methods for enzymatic DNA labeling. Nucleotides modified to carry functional or detectable groups are incorporated into newly synthesized DNA by DNA polymerases. DNA is synthesized from modified nucleoside triphosphates by DNA polymerases such that the newly synthesized DNA consists exclusively of modified nucleotides or contains modified nucleotides in high density. There are provided modified nucleoside triphosphates which are incorporated by DNA polymerases and a group of DNA polymerases which incorporate these nucleoside triphosphates in high density.
摘要翻译：本发明的主题是酶DNA标记的方法。经修饰以携带功能性或可检测基团的核苷酸通过DNA聚合酶并入新合成的DNA中。通过DNA聚合酶由修饰的核苷三磷酸合成DNA，使得新合成的DNA仅由修饰的核苷酸组成或含有高密度的修饰的核苷酸。提供了修饰的核苷三磷酸酯，其由DNA聚合酶和一组以高密度结合这些核苷三磷酸的DNA聚合酶结合。

3. 发明申请

WO0116149A2 2-AZAPURINE COMPOUNDS AND THEIR USE 审中-公开
标题翻译： 2-AZAPURINE化合物及其用途
公开(公告)号：WO0116149A2
公开(公告)日：2001-03-08
申请号：PCT/EP0008371
申请日：2000-08-28
申请人： ROCHE DIAGNOSTICS GMBH , SEELA FRANK , ROSEMEYER HELMUT , SCHWEINBERGER ENNO , HEINDL DIETER , BERGMANN FRANK
发明人： SEELA FRANK , ROSEMEYER HELMUT , SCHWEINBERGER ENNO , HEINDL DIETER , BERGMANN FRANK
IPC分类号： G01N33/53 , C07H19/04 , C07H19/10 , C07H19/20 , C07H21/00 , C12N15/09 , C12N15/113 , C12P19/34 , C12Q1/08 , C12Q1/68 , G01N33/566 , C07H19/00
CPC分类号： C12N15/113 , C07H19/04 , C07H19/10 , C07H19/20 , C07H21/00 , C12N2310/333 , C12Q1/6813
摘要： Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.
摘要翻译：寡核苷酸2-氮杂嘌呤，尤其是2-氮杂腺嘌呤碱基与鸟嘌呤特异性碱基对形成。该碱基对具有与腺嘌呤 - 胸腺嘧啶类似的稳定性，但不如鸟嘌呤 - 胞嘧啶碱基对稳定。因此，将2-氮杂腺嘌呤残基并入寡核苷酸而不是胞嘧啶，特别导致与具有均匀稳定性的核酸的杂交复合物。这对于在各种杂交技术中适应不同寡核苷酸序列的稳定性是有用的，例如在低聚物芯片技术中。

4. 发明专利

DE60132596T2 未知
公开(公告)号：DE60132596T2
公开(公告)日：2009-02-19
申请号：DE60132596
申请日：2001-07-31
申请人： ROCHE DIAGNOSTICS GMBH , HOFFMANN LA ROCHE
发明人： SEELA FRANK , BERGMANN FRANK , VON DER ELTZ HERBERT , HEINDL DIETER , SEIDEL CHRISTOPH , BECHER GEORG
IPC分类号： C07H19/16 , G01N33/53 , A61K31/7115 , A61K45/00 , A61K48/00 , C07H21/00 , C07H21/04 , C12N15/09 , C12P17/18 , C12Q1/68
摘要： The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.

5. 发明专利

JP2008113669A N8- and c8-linked purine base and structurally related heterocycle as universal nucleoside used for oligonucleotide hybridization 有权
标题翻译： N8-和C8-连接的碱基和结构相关的杂交体作为用于寡核苷酸杂交的通用核苷酸
公开(公告)号：JP2008113669A
公开(公告)日：2008-05-22
申请号：JP2008014190
申请日：2008-01-24
申请人： F Hoffmann La Roche Ag , エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft
发明人： SEELA FRANK , DEBELAK HARALD , BERGMANN FRANK , HEINDL DIETER , VON DER ELTZ HERBERT
IPC分类号： C12N15/09 , C12Q1/68 , A61K31/70 , C07H19/04 , C07H19/10 , C07H19/16 , C07H19/20 , C07H19/23 , C07H21/00 , C07H21/04
CPC分类号： C07H19/10 , C07H19/04 , C07H19/20 , C07H21/00
摘要： PROBLEM TO BE SOLVED: To provide a nucleic acid binding compound such as a primer or a probe including universal bases that can form better base pairs together with four natural bases together. SOLUTION: This is a nucleic acid binding compound including a detectable reporter group wherein the nucleic acid binding compound includes a back bone, on which a hetero ring group is attached, and can form base pairs together with natural bases. At least one of the hetero cycle groups is N 8 -glycocilated 8-aza-7-deaza-adenine. COPYRIGHT: (C)2008,JPO&INPIT
摘要翻译：要解决的问题：提供核酸结合化合物，例如引物或探针，包括能与四种天然碱基一起形成更好碱基对的通用碱基。解决方案：这是一种核酸结合化合物，其包括可检测的报告基团，其中核酸结合化合物包括其上附着杂环基团的背骨，并且可以与天然碱一起形成碱基对。至少一个杂循环基团是N-SP 8 - 糖化8-氮杂-7-去氮腺嘌呤。版权所有（C）2008，JPO＆INPIT

6. 发明申请

WO2004096197A2 5-AZA-7-DEAZAPURINE NUCLEOSIDES FOR TREATING FLAVIVIRIDAE 审中-公开
标题翻译：用于治疗火蜥蜴的5-AZA-7-二氮杂核苷
公开(公告)号：WO2004096197A2
公开(公告)日：2004-11-11
申请号：PCT/IB2004001740
申请日：2004-05-03
申请人： UNIV CAGLIARI , CENTRE NAT RECH SCIENT , UNI OSNABRUCK LAB FUR ORGANIC , LA COLLA PAOLO , GOSSELIN GILLES , SEELA FRANK , DUKHAN DAVID , LEROY FREDERIC
发明人： LA COLLA PAOLO , GOSSELIN GILLES , SEELA FRANK , DUKHAN DAVID , LEROY FREDERIC
IPC分类号： A61K31/00 , A61K31/522 , A61K31/708 , A61P31/20 , C07H19/12
CPC分类号： A61K31/708 , A61K31/00 , A61K31/522 , C07H19/12
摘要： This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-hepacivirus, anti-flavivirus or anti-pestivirus biologically active acyclic ester or pentofuranonucleoside that has a 5-aza-7-deazapurine nucleoside base. Also claimed are pharmaceutical compositions of the present invention that may be administered alone or in combination and/or alternation with another antiviral agent, and a use of these nucleoside analogues in the manufacture of a medicament.
摘要翻译：本发明涉及用于治疗感染丙型肝炎，黄病毒和/或瘟病毒的宿主，特别是人的方法，包括向该宿主施用有效量的抗肝病毒，抗黄病毒或抗瘟病毒的生物活性具有5-氮杂-7-脱氮嘌呤核苷碱基的无环酯或戊呋喃核苷。还要求保护的是本发明的药物组合物，其可以单独施用或与另一种抗病毒剂组合和/或交替施用，以及这些核苷类似物在制备药物中的用途。

7. 发明申请

WO2006000922A3 5-AZA-7-DEAZAPURINE DERIVATIVES FOR TREATING INFECTIONS WITH FLAVIVIRIDAE 审中-公开
标题翻译：用于治疗感染与氟虫腈的5-AZA-7-二氮嘌呤衍生物
公开(公告)号：WO2006000922A3
公开(公告)日：2006-05-26
申请号：PCT/IB2005002768
申请日：2005-06-23
申请人： IDENIX CAYMAN LTD , CENTRE NAT RECH SCIENT , UNIV CAGLIARI , UNIVERSTITAT OSNABRUCK LAB FUR , GOSSELIN GILLES , LA COLLA PAOLO , SEELA FRANK , STORER RICHARD , DUKHAN DAVID , LEROY FREDERIC
发明人： GOSSELIN GILLES , LA COLLA PAOLO , SEELA FRANK , STORER RICHARD , DUKHAN DAVID , LEROY FREDERIC
IPC分类号： A61K31/437 , A61K31/52 , A61K31/522 , A61K31/53 , A61P31/12
CPC分类号： C07D487/04 , A61K31/437 , A61K31/52 , A61K31/522 , A61K31/53 , C07D519/00
摘要： This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and may comprise a non-nucleoside or nucleoside analogue, or a salt or prodrug thereof. The compound of the present invention may be administered alone or in combination with another anti-hepatitis C, anti-flavivirus and/or anti-pestivirus agent.
摘要翻译：本发明涉及用于治疗感染丙型肝炎，黄病毒和/或瘟病毒的宿主，特别是人的方法，包括向该宿主施用有效量的抗黄病毒或抗瘟病毒，生物活性化合物具有 5-氮杂-7-脱氮嘌呤部分。 5-氮杂-7-脱氮嘌呤部分可以是取代或未取代的，并且可以包含非核苷或核苷类似物或其盐或前药。本发明的化合物可以单独施用或与另一种抗丙型肝炎，抗黄病毒和/或抗瘟病毒剂组合施用。

8. 发明申请

WO2004096197A8 5-AZA-7-DEAZAPURINE NUCLEOSIDES FOR TREATING FLAVIVIRIDAE 审中-公开
标题翻译：用于治疗黄疸病的5-氮杂-7-脱氮嘌呤核苷
公开(公告)号：WO2004096197A8
公开(公告)日：2005-04-14
申请号：PCT/IB2004001740
申请日：2004-05-03
申请人： UNIV CAGLIARI , CENTRE NAT RECH SCIENT , UNI OSNABRUCK LAB FUR ORGANIC , LA COLLA PAOLO , GOSSELIN GILLES , SEELA FRANK , DUKHAN DAVID , LEROY FREDERIC
发明人： LA COLLA PAOLO , GOSSELIN GILLES , SEELA FRANK , DUKHAN DAVID , LEROY FREDERIC
IPC分类号： A61K31/00 , A61K31/522 , A61K31/708 , A61P31/20 , C07H19/12 , A61K31/70
CPC分类号： A61K31/708 , A61K31/00 , A61K31/522 , C07H19/12
摘要： This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-hepacivirus, anti-flavivirus or anti-pestivirus biologically active acyclic ester or pentofuranonucleoside that has a 5-aza-7-deazapurine nucleoside base. Also claimed are pharmaceutical compositions of the present invention that may be administered alone or in combination and/or alternation with another antiviral agent, and a use of these nucleoside analogues in the manufacture of a medicament.
摘要翻译：本发明涉及一种治疗感染丙型肝炎，黄病毒和/或瘟病毒的宿主特别是人的方法，该方法包括给该宿主施用有效量的抗肝炎病毒，抗黄病毒或抗瘟病毒生物学活性无环酯或戊呋喃核苷，其具有5-氮杂-7-脱氮嘌呤核苷碱基。还要求保护本发明的药物组合物，其可以单独施用或与另一种抗病毒剂联合和/或交替施用，以及这些核苷类似物在制备药物中的用途。

9. 发明专利

CA2416631A1 NUCLEIC ACID BINDING COMPOUNDS CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE ANALOGUES OF PURIN-2,6-DIAMINE AND THEIR USES 未知
公开(公告)号：CA2416631A1
公开(公告)日：2002-02-14
申请号：CA2416631
申请日：2001-07-31
申请人： HOFFMANN LA ROCHE
发明人： BERGMANN FRANK , SEELA FRANK , BECHER GEORG , HEINDL DIETER , SEIDEL CHRISTOPH , VON DER ELTZ HERBERT
IPC分类号： G01N33/53 , A61K31/7115 , A61K45/00 , A61K48/00 , C07H19/16 , C07H21/00 , C07H21/04 , C12N15/09 , C12P17/18 , C12Q1/68 , C12Q1/02 , C12P19/26
摘要： The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and metho ds for the determination of nucleic acids using said compounds in the field of diagnostics.

10. 发明专利

ES2300346T3 COMPUESTOS DE ENLACE DE ACIDOS NUCLEICOS QUE CONTIENEN ANALOGOS DE PIRAZOLO-3,4-D PIRIMIDINA DE PURINA 2,6-DIAMINA Y SUS USOS. 未知
公开(公告)号：ES2300346T3
公开(公告)日：2008-06-16
申请号：ES01956576
申请日：2001-07-31
申请人： HOFFMANN LA ROCHE
发明人： SEELA FRANK , BERGMANN FRANK , VON DER ELTZ HERBERT , HEINDL DIETER , SEIDEL CHRISTOPH , BECHER GEORG
IPC分类号： C07H19/16 , G01N33/53 , A61K31/7115 , A61K45/00 , A61K48/00 , C07H21/00 , C07H21/04 , C12N15/09 , C12P17/18 , C12Q1/68
摘要： Una composición para analizar interacciones entre los compuestos de enlace de ácido nucleico, que comprende una serie de distribución de una pluralidad de compuestos de enlace de ácido nucleico, que tienen diferentes secuencias, en donde la citada pluralidad de compuestos de enlace de ácido nucleico, se acoplan a un substrato sólido, en localizaciones conocidas, y se seleccionan para enlazar los compuestos de enlace de ácido nucleicos complementarios, a cuyo efecto, solamente los compuestos de enlace de ácidos nucleicos, o los compuestos de enlace de ácidos nucleicos y los compuestos de enlace de ácidos nucleicos complementarios, son compuestos de enlace de ácido nucleico, que comprenden un esqueleto de la cadena, teniendo unidos, el citado esqueleto de la cadena, grupos heterocíclicos, capaces de aparear bases a nucleobases, caracterizada por el hecho de que, el grupo heterociclo, es un grupo de la fórmula general I (Ver fórmula) en donde, R1, es independiente de X, R2 ó R3, y es -F, -Cl, -Br. -I ó ciano; R2,R3, es independiente de X, R1, R2 y R3, y se selecciona de entre el grupo consistente en, (1) -H (2) alquilo(C1-C10) (3) alquenilo(C2-C10) (4) alquinilo(C2-C10) (5) arilo(C6-C22) (6) -Z-alquilo(C1-C10), -Z-alquenilo(C2-C10), -Z-al-quinilo(C2-C10), -Z-arilo(C6-C22) ó Z-H, en donde, A = -CO-, -CO-NH-, -CS-NH, -(CH2)n-[O-(CH2)r]s-, en donde, r y s, son, de una forma independiente la una con respecto a la otra, un número entero entre 1 a 18, y n, es 1 ó 2, independientemente de r y s, (7) sustituyentes (2) a (6), en donde, cualquier alquilo, alquinilo o arilo, puede sustituirse por uno o más porciones seleccionadas de entre el grupo consistente en -halógeno, -NO2, OR12, -CN, -SH, -S-alquilo(C1-C6), -NR5R6, -N+R5R6R12, -COR11, -NH-CONR5R6, -NH-CSNR5R6 y -(CH2)n-[O-(CH2)r]s-NR5R6, r y s, son, de una forma independiente la una con respecto a la otra, un número entero entre 1 a 18, y n, es 0 ó 1, independientemente de r y s, en donde, R11, se selecciona de entre el grupo consistente en -NHR12 y OR12, en donde, R5, R6 y R12, se seleccionan, de una forma independiente, de entre el grupo consistente en -H, -alquilo(C1-C10), -alque-nilo(C2-C10), -alquinilo(C2-C10), -arilo(C6-C22), y un grupo reportador, encontrándose insustituido, el citado alquilo, alquenilo, alquinilo o arilo, en las posiciones (2) a (7), o sustituido por una o más porciones seleccionadas de entre el grupo consistente en -halógeno, -SH, -S-alquilo(C1-C6), -alcoxi(C1-C6), -OH, -NR5R6, -COR11, -NH-CONR5R6, -NH-CSNR5R6 y -(CH2)n-[O-(CH2)r]s-NR5R6, r y s, son, de una forma independiente la una con respecto a la otra, un número entero entre 1 a 18, y n, es 0 ó 1, independientemente de r y s; X, es independiente de R1, R2 ó R3, y se selecciona de entre el grupo consistente en N y CH; D, es la posición de unión del grupo al residuo del compuesto de enlace de ácido nucleico; o cualesquiera sales de éstos.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式